Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03747653
Other study ID # CTR20182090
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 8, 2019
Est. completion date May 31, 2020

Study information

Verified date May 2020
Source Kaifeng Pharmaceutical (Group) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Primary objective: To assess the pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection at two dose levels in patients with hemophilia A.

Secondary objectives: To assess Safety and Tolerability by monitoring FVIII recovery and adverse events in patients with hemophilia A.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date May 31, 2020
Est. primary completion date May 31, 2020
Accepts healthy volunteers No
Gender Male
Age group 12 Years to 60 Years
Eligibility Inclusion Criteria:

- 12 years to 60 years, male.

- The activity of the coagulation factor VIII (FVIII:C) < 2%, and previously treated with FVIII concentrate (s) for a minimum of 150 exposure days (EDs) prior to study entry.

- Non-immune deficiency (CD4 > 200/µL).

- Non-acute hemorrhagic state.

- No history of a positive inhibitor test (< 0.6 BU) or clinical signs of decreased response to FVIII administrations. No Family history of inhibitors.

- Platelet count > 100,000 platelets/µL.

- Normal prothrombin time or INR < 1.3.

- Normal thrombin time (TT).

- Normal previous results of vWF antigen examination.

- Negative lupus anticoagulant .

- Capable of understanding and willing to comply with the conditions of the protocol have read (patient and/or guardian).

Exclusion Criteria:

- Hypersensitive to any of the excipients of the test materials (e.g. allergic to murine or hamster origin heterologous proteins).

- History of hypersensitivity or anaphylaxis associated with any FVIII or IgG2 administration.

- Current FVIII inhibitor-positive or history of FVIII inhibitor-positive.

- Other coagulation disorder(s) in addition to hemophilia A.

- Infusion of any products containing FVIII within 4 days prior screening or within 72 h prior to administration.

- Patients with severe heart disease, including myocardial infarction, heart failure (III or higher level).

- Clinically significant of other systematic diseases: alcoholism, drug abuse, mental disorders and mental retardation.

- Significant hepatic or renal impairment (ALT and AST > 2×ULN; serum bilirubin level > 3 × upper limit of normal (ULN) , BUN > 2×ULN, Cr > 2.0 mg/dL).

- One or more clinically significant tests for Human Immunodeficiency Virus (HIV), Antisyphilitic spirulina (TPHA) and Hepatitis C Virus (HCV) Antibody.

- Patients who received any anticoagulant or antiplatelet therapy within one week prior screening or need to receive an anticoagulant or antiplatelet therapy during the period of clinical trials.

- Patients having major surgery or receiving blood or bood components transfusion within 4 weeks prior screening or having planned major surgery schedule during the study.

- Patients who previously participated in the other clinical trials within 1 month prior screening.

- Any life-threatening disease or condition which, according to the investigator's judgment, could not benefit from the trial participation.

- Patient who is considered by the other investigators not suitable for clinical study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ADVATE
Patients will be administered a single dose of ADVATE.
FRSW107
Patients will be administered a single dose of FRSW107 for Injection.

Locations

Country Name City State
China Hematology Department, Beijing Children's Hospital, Capital Medical University Beijing
China Fujian Medical University Union Hospital Fuzhou Fujian
China Southern Medical University Nanfang Hospital Guangzhou Guangzhou
China Jinan Central Hospital Jinan Shandong
China Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin Tianjin

Sponsors (2)

Lead Sponsor Collaborator
Kaifeng Pharmaceutical (Group) Co., Ltd. Beijing Furen Biomedical Research Institute Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum measured concentration of FVIII:C (Cmax). Measured by the One-stage aPTT Clotting Assay. Pre-dose and post dose of FRSW107 up to 10 days.
Primary Time required for the concentration of the drug to reach half of its original value (T1/2). Measured by the One-stage aPTT Clotting Assay. Pre-dose and post dose of FRSW107 up to 10 days.
Primary Area Under the Curve to Infinity (AUC). Measured by the One-stage aPTT Clotting Assay. Pre-dose and post dose of FRSW107 up to 10 days.
Primary The measure of the efficiency of the body to remove the drug and the unit is the volume of the plasma or blood cleared of drug per unit time (CL). Measured by the One-stage aPTT Clotting Assay. Pre-dose and post dose of FRSW107 up to 10 days.
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE V5.0. Adverse events related to Recombinant Human Coagulation Factor VIII-Fc fusion protein for Injection according to Common Terminology Criteria for Adverse Events (CTCAE) NCI.V5.0. Post dose of FRSW107 up to 28.
Secondary Development of Inhibitor. Measured by the Nijmegen-Modified Bethesda Assay. Pre-dose and post dose of FRSW107 up to 28 days.
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Completed NCT04565236 - A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1